As the title suggests, the PBRER is an evaluation of the benefits of the product against the risks to ensure that the benefit-to-risk ratio is still positive for the product.
This article summarizes the provisions of the final 2026 HHS Notice of Benefit Payment Parameters related to the individual ...
The results are "reassuring regarding the risk/benefit ratio for the long term use of GLP-1 receptor agonists in people with diabetes," O'Rahilly said.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback